Market Cap 74.92M
Revenue (ttm) 0.00
Net Income (ttm) -149.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 290,700
Avg Vol 567,964
Day's Range N/A - N/A
Shares Out 61.92M
Stochastic %K 23%
Beta 1.23
Analysts Hold
Price Target $2.67

Company Profile

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based t...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 481 6770
Address:
331 Oyster Point Boulevard, South San Francisco, United States
SQUEAKSBANDIT
SQUEAKSBANDIT Apr. 28 at 9:27 PM
$PLRX i've been away for a few did the poison pill expire or was it renewed
0 · Reply
THSSKS
THSSKS Apr. 24 at 4:12 PM
$PLRX the pipeline sucks. That’s the problem. Too much competition with their treatment. Management is intent on blowing hundreds of millions on a long shot and offerings too.
1 · Reply
Lukey63
Lukey63 Apr. 22 at 2:02 PM
$PLRX Started position today. Cheap, reasonable cash burn and has some promise.
0 · Reply
ka1954
ka1954 Apr. 20 at 1:51 PM
$PLRX every fucking nano biotech stock goes down on any news. fucking pieces of crap. only 5% stocks go up on news
0 · Reply
AlertsAndNews
AlertsAndNews Apr. 19 at 10:15 PM
$PLRX Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting "Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months"
0 · Reply
DonCorleone77
DonCorleone77 Apr. 19 at 5:34 PM
$PLRX Pliant announces presentation of updated data from Phase 1 trial of PLN-101095 Pliant Therapeutics announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. The oral presentation was made at the Clinical Trials Mini Symposium of the American Association for Cancer Research (AACR) 2026 Annual Meeting. All responding patients showed large increases in plasma interferon gamma after a 14-day run-in period of monotherapy with PLN-101095. At Week 10, all responders maintained more than a 2-fold increase in IFN-gamma. No non-responders showed meaningful increases in IFN- gamma. In addition to IFN- gamma increases, all responding patients showed elevated plasma PD-L1 levels, known to be induced by increased IFN-gamma and a predictor of an improved ICI response. As increases in IFN-gamma have the potential to serve as a biomarker of TGF-beta inhibition and an early indicator of PLN-101095 anti-tumor activity. Pliant anticipates further study of this biomarker as part of the expansion cohorts in the Phase 1b trial. PLN-101095 was generally well tolerated across all doses evaluated with few discontinuations due to adverse events. Rash was the most common treatment-related adverse event, all Grade 1 or 2, and the majority of events occurred within the first 2 days of the initial pembrolizumab dose. One Grade 3 TRAE was observed.
0 · Reply
THSSKS
THSSKS Apr. 19 at 6:03 AM
$PLRX aarc was so so, nothing great and nothing bad. Going to take to phase 2 data for movement imo. 1 CR is great, but need way more people. They should’ve just announced bad news and announced they’re liquidating company and give SH’s $2.50/share.
0 · Reply
focafoca99
focafoca99 Apr. 18 at 7:53 PM
$PLRX Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting https://www.rapidticker.com/news/plrx-pliant-therapeutics-announces-presentation-of-dbdf8e
0 · Reply
islandpunk
islandpunk Apr. 18 at 7:24 PM
$PLRX https://www.stocktitan.net/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-ulf0avsm5sfq.html
0 · Reply
JamesPond007
JamesPond007 Apr. 17 at 1:22 PM
$PLRX p1 trial tomorrow. When did you see negative trial data shared on a weekend on p1? Rare.
0 · Reply
Latest News on PLRX
Pliant Therapeutics Provides Update on BEACON-IPF

Jun 27, 2025, 4:05 PM EDT - 10 months ago

Pliant Therapeutics Provides Update on BEACON-IPF


Pliant Therapeutics Transcript: Study Update

Feb 5, 2024, 8:00 AM EST - 2 years ago

Pliant Therapeutics Transcript: Study Update


Pliant Therapeutics Transcript: Study Result

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Pliant Therapeutics Transcript: Study Result


Pliant Therapeutics Transcript: Study Result

May 1, 2023, 8:00 AM EDT - 3 years ago

Pliant Therapeutics Transcript: Study Result


Pliant Therapeutics Transcript: Status Update

May 1, 2023, 8:00 AM EDT - 3 years ago

Pliant Therapeutics Transcript: Status Update


Pliant Therapeutics Transcript: Needham Healthcare Conference

Apr 19, 2023, 3:45 PM EDT - 3 years ago

Pliant Therapeutics Transcript: Needham Healthcare Conference


Pliant Therapeutics Transcript: Study Result

Jan 23, 2023, 8:00 AM EST - 3 years ago

Pliant Therapeutics Transcript: Study Result


Pliant Therapeutics Transcript: Status Update

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Pliant Therapeutics Transcript: Status Update


SQUEAKSBANDIT
SQUEAKSBANDIT Apr. 28 at 9:27 PM
$PLRX i've been away for a few did the poison pill expire or was it renewed
0 · Reply
THSSKS
THSSKS Apr. 24 at 4:12 PM
$PLRX the pipeline sucks. That’s the problem. Too much competition with their treatment. Management is intent on blowing hundreds of millions on a long shot and offerings too.
1 · Reply
Lukey63
Lukey63 Apr. 22 at 2:02 PM
$PLRX Started position today. Cheap, reasonable cash burn and has some promise.
0 · Reply
ka1954
ka1954 Apr. 20 at 1:51 PM
$PLRX every fucking nano biotech stock goes down on any news. fucking pieces of crap. only 5% stocks go up on news
0 · Reply
AlertsAndNews
AlertsAndNews Apr. 19 at 10:15 PM
$PLRX Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting "Confirmed responses deepened with an average maximum tumor reduction from baseline of 89% and median time on treatment increased to 19 months"
0 · Reply
DonCorleone77
DonCorleone77 Apr. 19 at 5:34 PM
$PLRX Pliant announces presentation of updated data from Phase 1 trial of PLN-101095 Pliant Therapeutics announced the presentation of updated data from its Phase 1 trial of PLN-101095, in combination with pembrolizumab, in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors. The oral presentation was made at the Clinical Trials Mini Symposium of the American Association for Cancer Research (AACR) 2026 Annual Meeting. All responding patients showed large increases in plasma interferon gamma after a 14-day run-in period of monotherapy with PLN-101095. At Week 10, all responders maintained more than a 2-fold increase in IFN-gamma. No non-responders showed meaningful increases in IFN- gamma. In addition to IFN- gamma increases, all responding patients showed elevated plasma PD-L1 levels, known to be induced by increased IFN-gamma and a predictor of an improved ICI response. As increases in IFN-gamma have the potential to serve as a biomarker of TGF-beta inhibition and an early indicator of PLN-101095 anti-tumor activity. Pliant anticipates further study of this biomarker as part of the expansion cohorts in the Phase 1b trial. PLN-101095 was generally well tolerated across all doses evaluated with few discontinuations due to adverse events. Rash was the most common treatment-related adverse event, all Grade 1 or 2, and the majority of events occurred within the first 2 days of the initial pembrolizumab dose. One Grade 3 TRAE was observed.
0 · Reply
THSSKS
THSSKS Apr. 19 at 6:03 AM
$PLRX aarc was so so, nothing great and nothing bad. Going to take to phase 2 data for movement imo. 1 CR is great, but need way more people. They should’ve just announced bad news and announced they’re liquidating company and give SH’s $2.50/share.
0 · Reply
focafoca99
focafoca99 Apr. 18 at 7:53 PM
$PLRX Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting https://www.rapidticker.com/news/plrx-pliant-therapeutics-announces-presentation-of-dbdf8e
0 · Reply
islandpunk
islandpunk Apr. 18 at 7:24 PM
$PLRX https://www.stocktitan.net/news/PLRX/pliant-therapeutics-announces-presentation-of-updated-data-from-the-ulf0avsm5sfq.html
0 · Reply
JamesPond007
JamesPond007 Apr. 17 at 1:22 PM
$PLRX p1 trial tomorrow. When did you see negative trial data shared on a weekend on p1? Rare.
0 · Reply
THSSKS
THSSKS Apr. 14 at 2:03 PM
0 · Reply
THSSKS
THSSKS Apr. 3 at 5:45 AM
$PLRX inverse head and shoulders going into a major catalyst (AARC). I’m keeping expectations low because Tang wants it, but this one has huge potential. Likewise, I don’t think $CON would mind if it runs hundreds of % either. Win win for them.
0 · Reply
THSSKS
THSSKS Mar. 31 at 4:24 PM
$PLRX bankers might pump this for the ATM and shelf offering. I’m taking a chance holding this junk, but I’m hoping it plays out like AMLX from roughly $1.5-$17. I’m definitely not a scientist, so I’m putting blind faith into their pipeline and using their current cash as a safety net at these depressed levels.
1 · Reply
focafoca99
focafoca99 Mar. 31 at 1:41 AM
$PLRX quietly swapped financing tools here, terminating the old Cantor ATM and setting up a new Leerink at-the-market program for up to $50M.
0 · Reply
THSSKS
THSSKS Mar. 24 at 3:34 PM
$PLRX lower lows/highs for 2 weeks now. These punks need to start buying on open market since they cok blocked selling the company with their poison pill. Probably another fund dumping while they are busy creating no shareholder value
1 · Reply
THSSKS
THSSKS Mar. 20 at 6:04 AM
$PLRX amazing this went down/flat after being selected for AACR. Only a fraction of applicants are selected to be in. Hedgies might be accumulating to run it up next month after the meeting, usually only “best in class” make it which is why I’m surprised it went down after the news. Big investors will be watching April 18th. I’d like to see a big player like $MRK opt in here and give milestone payments. This could easily run 500% + if so. I bought back my position after that tiny sell off. Still close to $200M here with an $82MM mkt cap and a good portion of the float locked up. Downside limited because of cash, I’d think if pln-101095 failed, they’d at least remove the poison pill and let Tang buy the company for the cash or reverse merger..
1 · Reply
THSSKS
THSSKS Mar. 16 at 6:00 PM
$PLRX I can’t see the reports from Piper and Cannacord, but analysts must think the pipeline is worth absolute dog shit if they’re giving this a $3 pt which is near liquidation prices. Someone is relentlessly selling blocks the last couple of days too, definitely a fund that wants out. I was in this for a buyout which isn’t happening now, so good luck to everyone. I’m not letting this turn into another KZR who is still doing nothing after 2 years of poison pills to stop Tang, they had way more cash to market cap than plrx too 2 years ago. Management is screwing shareholders here pursuing new pipeline instead of finding alternatives. ✌️
1 · Reply
Stockboi_
Stockboi_ Mar. 13 at 5:47 PM
$PLRX need to hold support and we see higher. Strong daily chart
0 · Reply
NorthStarStats
NorthStarStats Mar. 13 at 11:57 AM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $APD Score: 100, $MOS Score: 95, $PLRX Score 71, $SBUX Score 70, $AWK Score 70
0 · Reply
anachartanalyst
anachartanalyst Mar. 12 at 5:02 PM
$PLRX https://anachart.com/wp-content/uploads/ana_temp/1773334907_soc-img.jpg
0 · Reply
sandman7473
sandman7473 Mar. 12 at 2:13 PM
$PLRX inverse head and shoulders setting up.
0 · Reply
THSSKS
THSSKS Mar. 12 at 3:45 AM
$PLRX overall data is encouraging but only 10 patients. This might need bigger phase 2 data to pop, hopefully I’m wrong but I don’t think so. roughly 2m patients worldwide receive checkpoint inhibitors. ~$100,000 per person implies a multi billion TAM. Board needs to buy stock
1 · Reply